Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted treatment strategies for functional dyspepsia with mood disorders
ChiCTR2100053126Phase 4Completed
- Sponsor
- Third Xiangya Hospital, Central South University
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of flupentixol, melitracen, nizatidine and rabeprazole in functional dyspepsia (FD), anxiety disorder and major depressive disorder (MDD) (5 arms), sponsored by Third Xiangya Hospital, Central South University. Primary endpoints: Gastrointestinal symptom scores, Anxiety scores and 1 more. Started Jan 2019; status: completed.
02
Drugs
flupentixolmelitracennizatidinerabeprazole
03
Conditions
functional dyspepsia (FD)anxiety disordermajor depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2100053126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053126.